Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 25;24(11):9248.
doi: 10.3390/ijms24119248.

MYD88 and Proinflammatory Chemokines in Aortic Atheromatosis: Exploring Novel Statin Effects

Affiliations

MYD88 and Proinflammatory Chemokines in Aortic Atheromatosis: Exploring Novel Statin Effects

Konstantinos S Mylonas et al. Int J Mol Sci. .

Abstract

Atherosclerosis is driven by a diverse range of cellular and molecular processes. In the present study, we sought to better understand how statins mitigate proatherogenic inflammation. 48 male New Zealand rabbits were divided into eight groups, each including 6 animals. The control groups received normal chow for 90 and 120 days. Three groups underwent a hypercholesterolemic diet (HCD) for 30, 60, and 90 days. Another three groups underwent HCD for 3 months, followed by normal chow for one month, with or without rosuvastatin or fluvastatin. The cytokine and chemokine expressions were assessed in the samples of thoracic and abdominal aorta. Rosuvastatin significantly reduced MYD88, CCL4, CCL20, CCR2, TNF-α, IFN-β, IL-1b, IL-2, IL-4, IL-8, and IL-10, both in the thoracic and abdominal aorta. Fluvastatin also downregulated MYD88, CCR2, IFN-β, IFN-γ, IL-1b, IL-2, IL-4, and IL-10 in both aortic segments. Rosuvastatin curtailed the expression of CCL4, IFN-β, IL-2, IL-4, and IL-10 more effectively than fluvastatin in both types of tissue. MYD88, TNF-α, IL-1b, and IL-8 showed a stronger downregulation with rosuvastatin compared to fluvastatin only in the thoracic aorta. The CCL20 and CCR2 levels reduced more extensively with rosuvastatin treatment only in abdominal aortic tissue. In conclusion, statin therapy can halt proatherogenic inflammation in hyperlipidemic animals. Rosuvastatin may be more effective in downregulating MYD88 in atherosclerotic thoracic aortas.

Keywords: CCL20; CCL4; CCR2; MYD88; atherosclerosis; statin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Effects of a high-fat diet and statin treatment on the thoracic rabbit aorta. (a) MYD88; (b) NF-kB; (c) CCL4; (d) CCL20; (e) CCR2; (f) IFNβ; (g) IFNγ; (h) TNFα; (i) IL-1b; (j) IL-2; (k) IL-4; (l) IL-8; (m) IL-10; (n) IL-18. Significant difference (p < 0.05) versus C90 (*), C120 (#), G30 (a), G60 (b), G90 (c), G120 (d), and GF120 (e).
Figure 2
Figure 2
Effects of a high-fat diet and statin treatment on the abdominal rabbit aorta. (a) MYD88; (b) NF-kB; (c) CCL4; (d) CCL20; (e) CCR2; (f) IFNβ; (g) IFNγ; (h) TNFα; (i) IL-1b; (j) IL-2; (k) IL-4; (l) IL-8; (m) IL-10; (n) IL-18. Significant difference (p < 0.05) versus C90 (*), C120 (#), G30 (a), G60 (b), G90 (c), G120 (d), and GF120 (e).

References

    1. Benjamin E.J., Blaha M.J., Chiuve S.E., Cushman M., Das S.R., Deo R., de Ferranti S.D., Floyd J., Fornage M., Gillespie C., et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017;135:e146–e603. doi: 10.1161/CIR.0000000000000485. - DOI - PMC - PubMed
    1. Heidenreich P.A., Trogdon J.G., Khavjou O.A., Butler J., Dracup K., Ezekowitz M.D., Finkelstein E.A., Hong Y., Johnston S.C., Khera A., et al. Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. Circulation. 2011;123:933–944. doi: 10.1161/CIR.0b013e31820a55f5. - DOI - PubMed
    1. Getz G.S., Reardon C.A. Atherogenic lipids and macrophage subsets. Curr. Opin. Lipidol. 2015;26:357–361. doi: 10.1097/MOL.0000000000000217. - DOI - PubMed
    1. Gomez D., Owens G.K. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc. Res. 2012;95:156–164. doi: 10.1093/cvr/cvs115. - DOI - PMC - PubMed
    1. Hansson G.K., Hermansson A. The immune system in atherosclerosis. Nat. Immunol. 2011;12:204–212. doi: 10.1038/ni.2001. - DOI - PubMed

MeSH terms